Super-enhancer-driven SLCO4A1-AS1 is a New Biomarker and a Promising Therapeutic Target in Glioblastoma

Overview

Journal Sci Rep

Specialty Science

Date 2025 Jan 6

PMID 39762261

Authors

Yibo Wu

Fang Li

Chen Yang

Xuehai Zhang

Zhiwei Xue

Yanfei Sun

Xiaoying Lin

Xuemeng Liu

Zhimin Zhao

Bin Huang

Qibing Huang

Xingang Li

Mingzhi Han

Affiliations

Soon will be listed here.

Abstract

Glioblastoma (GBM) is the most common intracranial malignancy, but current treatment options are limited. Super-enhancers (SEs) have been found to drive the expression of key oncogenes in GBM. However, the role of SE-associated long non-coding RNAs (lncRNAs) in GBM remains poorly understood. Here, we screened for an up-regulated lncRNA-SLCO4A1-AS1 expressed in GBM by analyzing data from GSE54791, GSE4536 and TCGA. We systematically analyzed its relationship with clinical characteristics, prognosis, epigenetics, tumor microenvironment (TME), biological functions, and transcription factors. We found that SE-driven SLCO4A1-AS1 was significantly upregulated in GBM and correlated with poor prognosis. Knockdown of SLCO4A1-AS1 decreased glioma cell proliferation, invasive ability, self-renewal ability, and increased apoptosis. Epigenetic analysis revealed that SOX2 and SE could drive SLCO4A1-AS1 expression. In vitro experiments further demonstrated that GBM cells with high SLCO4A1-AS1 expression were more sensitive to VX-11e, and overexpression of SLCO4A1-AS1 could reverse the inhibitory effect of VX-11e on GBM cells. In conclusion, this study revealed that SE-driven SLCO4A1-AS1 may be a potential therapeutic target in GBM.

References

Rizvi N, Hellmann M, Snyder A, Kvistborg P, Makarov V, Havel J . Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348(6230):124-8. PMC: 4993154. DOI: 10.1126/science.aaa1348. View

Atianand M, Caffrey D, Fitzgerald K . Immunobiology of Long Noncoding RNAs. Annu Rev Immunol. 2017; 35:177-198. PMC: 6449690. DOI: 10.1146/annurev-immunol-041015-055459. View

Zhang M, Bai Y, Xu C, Qi Y, Meng J, Zhang W . Blockage of Extracellular Signal-Regulated Kinase Exerts an Antitumor Effect via Regulating Energy Metabolism and Enhances the Efficacy of Autophagy Inhibitors by Regulating Transcription Factor EB Nuclear Translocation in Osteosarcoma. Front Cell Dev Biol. 2021; 9:650846. PMC: 8369911. DOI: 10.3389/fcell.2021.650846. View

Wang Z, Zhong H, Liang X, Ni S . Targeting tumor-associated macrophages for the immunotherapy of glioblastoma: Navigating the clinical and translational landscape. Front Immunol. 2022; 13:1024921. PMC: 9606568. DOI: 10.3389/fimmu.2022.1024921. View

Cai J, Hu Y, Ye Z, Ye L, Gao L, Wang Y . Immunogenic cell death-related risk signature predicts prognosis and characterizes the tumour microenvironment in lower-grade glioma. Front Immunol. 2022; 13:1011757. PMC: 9618960. DOI: 10.3389/fimmu.2022.1011757. View

Deorah S, Lynch C, Sibenaller Z, Ryken T . Trends in brain cancer incidence and survival in the United States: Surveillance, Epidemiology, and End Results Program, 1973 to 2001. Neurosurg Focus. 2006; 20(4):E1. DOI: 10.3171/foc.2006.20.4.E1. View

Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf A . Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity. 2013; 39(4):782-95. DOI: 10.1016/j.immuni.2013.10.003. View

Yoshihara K, Shahmoradgoli M, Martinez E, Vegesna R, Kim H, Torres-Garcia W . Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013; 4:2612. PMC: 3826632. DOI: 10.1038/ncomms3612. View

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y . TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018; 554(7693):544-548. PMC: 6028240. DOI: 10.1038/nature25501. View

10.

Gabrusiewicz K, Ellert-Miklaszewska A, Lipko M, Sielska M, Frankowska M, Kaminska B . Characteristics of the alternative phenotype of microglia/macrophages and its modulation in experimental gliomas. PLoS One. 2011; 6(8):e23902. PMC: 3162015. DOI: 10.1371/journal.pone.0023902. View

11.

Ozgiray E, Sogutlu F, Biray Avci C . Chk1/2 inhibitor AZD7762 enhances the susceptibility of IDH-mutant brain cancer cells to temozolomide. Med Oncol. 2022; 39(11):166. DOI: 10.1007/s12032-022-01769-x. View

12.

Naranbhai V, Viard M, Dean M, Groha S, Braun D, Labaki C . HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study. Lancet Oncol. 2021; 23(1):172-184. PMC: 8742225. DOI: 10.1016/S1470-2045(21)00582-9. View

13.

Jongsma M, de Waard A, Raaben M, Zhang T, Cabukusta B, Platzer R . The SPPL3-Defined Glycosphingolipid Repertoire Orchestrates HLA Class I-Mediated Immune Responses. Immunity. 2020; 54(1):132-150.e9. PMC: 8722104. DOI: 10.1016/j.immuni.2020.11.003. View

14.

Di W, Fan W, Wu F, Shi Z, Wang Z, Yu M . Clinical characterization and immunosuppressive regulation of CD161 (KLRB1) in glioma through 916 samples. Cancer Sci. 2021; 113(2):756-769. PMC: 8819299. DOI: 10.1111/cas.15236. View

15.

Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin N . Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006; 9(5):391-403. DOI: 10.1016/j.ccr.2006.03.030. View

16.

Yang Y, Wang F, Huang H, Zhang Y, Xie H, Men T . lncRNA SLCO4A1-AS1 promotes growth and invasion of bladder cancer through sponging miR-335-5p to upregulate OCT4. Onco Targets Ther. 2019; 12:1351-1358. PMC: 6389014. DOI: 10.2147/OTT.S191740. View

17.

Zhu H, Hu X, Gu L, Jian Z, Li L, Hu S . TUBA1C is a Prognostic Marker in Low-grade Glioma and Correlates with Immune Cell Infiltration in the Tumor Microenvironment. Front Genet. 2021; 12:759953. PMC: 8553001. DOI: 10.3389/fgene.2021.759953. View

18.

Jasek-Gajda E, Jurkowska H, Jasinska M, Litwin J, Lis G . Combination of ERK2 inhibitor VX-11e and voreloxin synergistically enhances anti-proliferative and pro-apoptotic effects in leukemia cells. Apoptosis. 2019; 24(11-12):849-861. PMC: 6823322. DOI: 10.1007/s10495-019-01564-6. View

19.

Zhou W, Li J . Integrated Analysis of Genes Associated With Immune Microenvironment and Distant Metastasis in Uveal Melanoma. Front Cell Dev Biol. 2022; 10:874839. PMC: 9006059. DOI: 10.3389/fcell.2022.874839. View

20.

Aran D, Sirota M, Butte A . Systematic pan-cancer analysis of tumour purity. Nat Commun. 2015; 6:8971. PMC: 4671203. DOI: 10.1038/ncomms9971. View